NewsBenzingaCardiol Therapeutics Announces Enrollment Progress And Plans To Expand Its MAVERIC Phase III Trial Evaluating CardiolRx For Risk Reduction Of Recurrence In Patients With Recurrent Pericarditis Cardiol Therapeutics Announces Enrollment Progress And Plans To Expand Its MAVERIC Phase III Trial Evaluating CardiolRx For Risk Reduction Of Recurrence In Patients With Recurrent Pericarditis Benzinga 2026.09.23 10:02 (GMT+0) Open on Benzinga Other news If Apple Cuts iPhone Units in 2027, This Stock Could Be a Big Loser Trust company AnchorWatch Trust Company launches Bitcoin custody service Wells Fargo Maintains Equal-Weight on PENN Entertainment, Lowers Price Target to $22 HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $85 Price Target Alphabet Stock Rises: What's Going On? $1000 Invested In Agilent Technologies 10 Years Ago Would Be Worth This Much Today
